Bilaketaren emaitzak - Daniel J. DeAngelo

Findu emaitzak
  1. 1
    Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia

    Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia nork Shai Shimony, Daniel J. DeAngelo, Marlise R. Luskin

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    New Approaches to the Management of Adult Acute Lymphoblastic Leukemia

    New Approaches to the Management of Adult Acute Lymphoblastic Leukemia nork Renato Bassan, Jean‐Pierre Bourquin, Daniel J. DeAngelo, Sabina Chiaretti

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Novel <i>SSBP2‐JAK2</i> fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia

    Novel <i>SSBP2‐JAK2</i> fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre‐B acute lymphocytic leukemia nork Jennifer L. Poitras, Paola Dal Cin, Jon C. Aster, Daniel J. DeAngelo, Cynthia C. Morton

    Argitaratua 2008
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Invasive fungal disease in patients treated for newly diagnosed acute leukemia

    Invasive fungal disease in patients treated for newly diagnosed acute leukemia nork Sarah P. Hammond, Francisco M. Marty, Julie M. Bryar, Daniel J. DeAngelo, Lindsey R. Baden

    Argitaratua 2010
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Gefitinib induces myeloid differentiation of acute myeloid leukemia

    Gefitinib induces myeloid differentiation of acute myeloid leukemia nork Kimberly Stegmaier, Steven M. Corsello, Kenneth N. Ross, Jenny Wong, Daniel J. DeAngelo, Todd R. Golub

    Argitaratua 2005
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    SYK regulates mTOR signaling in AML

    SYK regulates mTOR signaling in AML nork Julia Carnevale, Linda Ross, Alexandre Puissant, Versha Banerji, Richard M. Stone, Daniel J. DeAngelo, Kenneth N. Ross, Kimberly Stegmaier

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

    Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review nork Jorge E. Cortés, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi Kota, Philippe Rousselot, Carlo Gambacorti‐Passerini

    Argitaratua 2018
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH

    The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH nork Jeffrey I. Zwicker, Tzu‐Fei Wang, Daniel J. DeAngelo, Mandy N. Lauw, Jean M. Connors, Anna Falanga, Malgorzata McMasters, Marc Carrier

    Argitaratua 2020
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  9. 9
    The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consortium protocols

    The frequency and management of asparaginase‐related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana‐Farber Cancer Institute consorti... nork Rachael F. Grace, Suzanne E. Dahlberg, Donna Neuberg, Stephen E. Sallan, Jean M. Connors, Ellis J. Neufeld, Daniel J. DeAngelo, Lewis B. Silverman

    Argitaratua 2011
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome

    Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome nork Edwin P. Alyea, Haesook T. Kim, Vincent T. Ho, Corey Cutler, Daniel J. DeAngelo, Richard M. Stone, Jerome Ritz, Joseph H. Antin, Robert J. Soiffer

    Argitaratua 2006
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  11. 11
    A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

    A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia nork Aaron D. Schimmer, Azra Raza, Thomas H. Carter, David F. Claxton, Harry P. Erba, Daniel J. DeAngelo, Martin S. Tallman, Carolyn A. Goard, Gautam Borthakur

    Argitaratua 2014
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

    Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML nork Thanh‐Trang Vo, Jeremy Ryan, Ruben D. Carrasco, Donna Neuberg, Derrick J. Rossi, Richard M. Stone, Daniel J. DeAngelo, Mark G. Frattini, Anthony Letai

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts

    Clinical use of measurable residual disease in adult ALL: recommendations from a panel of U.S. experts nork Nicholas J. Short, Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica T. Leonard, Aaron C. Logan, Jae H. Park, Bijal Shah, Wendy Stock, Elias Jabbour

    Argitaratua 2025
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

    Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes nork Alexander E. Sherman, Gabriela Motyckova, K. Rebecca Fega, Daniel J. DeAngelo, Gregory A. Abel, David P. Steensma, Martha Wadleigh, Richard M. Stone, Jane A. Driver

    Argitaratua 2013
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  15. 15
    Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation

    Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation nork Philippe Armand, Haesook T. Kim, Daniel J. DeAngelo, Vincent T. Ho, Corey Cutler, Richard M. Stone, Jerome Ritz, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535) nork Jeffrey E. Lancet, Anna Moseley, Steven Coutré, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients

    Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients nork Shai Shimony, Jacqueline S. Garcia, Julia Keating, Evan C. Chen, Marlise R. Luskin, Maximilian Stahl, Donna Neuberg, Daniel J. DeAngelo, Richard M. Stone, R. Coleman Lindsley

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 198... nork Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven Coutré, Richard M. Stone, Alison Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

    Argitaratua 2007
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia

    Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia nork Patrick Bhola, Brenton G. Mar, R. Coleman Lindsley, Jeremy Ryan, Leah J. Hogdal, Thanh Trang Vo, Daniel J. DeAngelo, Ilene Galinsky, Benjamin L. Ebert, Anthony Letai

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

    A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Synd... nork Amer M. Zeidan, Daniel J. DeAngelo, Jeanne Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Ying Fei Li, Nanette Hock, Michael R. Burgess, Kristen Hege, Wendy Stock

    Argitaratua 2019
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: